PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Vinpocetine (a synthetic ethyl ester of the Vinca minor alkaloid apovincamine) has been used in human treatment for over twenty years, though it is not approved by regulatory bodies for cognitive impairment; the relevance of basic science to clinical studies remains unclear [PMID:12535455].
Complementary use of dwarf periwinkle (Vinca minor) may have a greater therapeutic effect than current pharmaceutical drugs alone due to neuroprotective and antioxidant bioactive components [PMID:28095073].
Alkaloid extracts of Vinca minor showed dose-dependent cytotoxic effects on HT-29, Caco-2, T47D, and NIH/3T3 cell lines [PMID:20645762].
Evidence summary
PubMed sources
- 1.PMID: 20645762 (2010) — Cytotoxicity of Vinca minor. · Pharmaceutical biology
- 2.PMID: 12535455 (2003) — Vinpocetine for cognitive impairment and dementia. · The Cochrane database of systematic reviews
- 3.PMID: 36200869 (2022) — The Vinca minor genome highlights conserved evolutionary traits in monoterpene indole alkaloid synthesis. · G3 (Bethesda, Md.)
- 4.PMID: 28095073 (2017) — Preclinical and Potential Applications of Common Western Herbal Supplements as Complementary Treatment in Parkinson's Disease. · Journal of dietary supplements
- 5.PMID: 24250413 (2011) — Phytochemical Investigation of Vinca minor Cultivated in Iran.